The nanomedicine market, valued at USD 223.6 billion in 2023, is projected to reach USD 634.2 billion by 2032, driven by advanced drug delivery systems and rising chronic diseases. Key players include Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries. Recent developments include Novartis's nanoparticle-based ovarian cancer treatment and Merck's partnership with Stanford for immunotherapy research.